GRO and NAP2 levels were significantly higher in PAD patients’ plasma, and NAP2 (AUC: 0.752) demonstrated a better diagnostic performance for PAD patients as compared with GRO (AUC: 0.670) (Fig. 6D). This evidence concerns the gene CXCL1 and peripheral arterial disease.